Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email

Corvus Pharmaceuticals (CRVS) News Today

→ Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad)
Free CRVS Stock Alerts
$2.29
0.00 (0.00%)
(As of 02:07 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
May 20 at 9:46 AM | stockhouse.com
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Corvus Pharmaceuticals, Inc. (CRVS) and Encourages Investors to Contact the Firm
May 15, 2024 | marketbeat.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Above 50 Day Moving Average of $1.77
Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Crosses Above 50-Day Moving Average of $1.77
May 12, 2024 | finance.yahoo.com
13 Penny Stocks with Insider Buying in 2024
May 10, 2024 | finance.yahoo.com
Insider Spends US$1m Buying More Shares In Corvus Pharmaceuticals
May 8, 2024 | insidertrades.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Purchases $34,600.00 in Stock
May 7, 2024 | marketbeat.com
William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) insider William Benton Jones acquired 20,000 shares of the stock in a transaction dated Monday, May 6th. The shares were purchased at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the transaction, the insider now owns 153,773 shares of the company's stock, valued at approximately $266,027.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
May 7, 2024 | finance.yahoo.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript
May 7, 2024 | finanznachrichten.de
Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 7, 2024 | finance.yahoo.com
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
May 7, 2024 | marketbeat.com
Oppenheimer Increases Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target to $8.00
Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Tuesday.
May 7, 2024 | finance.yahoo.com
Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 6, 2024 | globenewswire.com
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 3, 2024 | marketbeat.com
Corvus Pharmaceuticals (CRVS) Set to Announce Earnings on Monday
Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings after the market closes on Monday, May 6, Zacks reports.
May 2, 2024 | globenewswire.com
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
May 2, 2024 | globenewswire.com
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
April 24, 2024 | finance.yahoo.com
Corvus Pharmaceuticals, Inc. (CRVS)
April 17, 2024 | finance.yahoo.com
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
April 16, 2024 | marketbeat.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 6.0% in March
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 1,400,000 shares, a decrease of 6.0% from the March 15th total of 1,490,000 shares. Currently, 3.8% of the shares of the stock are sold short. Based on an average trading volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days.
April 9, 2024 | globenewswire.com
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
April 4, 2024 | marketbeat.com
Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) pe
April 1, 2024 | marketbeat.com
Cantor Fitzgerald Reaffirms Overweight Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Monday.
March 27, 2024 | marketbeat.com
Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
Mizuho reaffirmed a "neutral" rating and set a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday.
March 21, 2024 | seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
March 21, 2024 | finance.yahoo.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
March 21, 2024 | finanznachrichten.de
Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 20, 2024 | marketbeat.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Lowered to $7.00 at Oppenheimer
Oppenheimer cut their price target on Corvus Pharmaceuticals from $8.00 to $7.00 and set an "outperform" rating for the company in a research note on Wednesday.
March 20, 2024 | finance.yahoo.com
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
March 19, 2024 | stockhouse.com
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024 | globenewswire.com
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 18, 2024 | marketbeat.com
Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Tuesday
Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.
March 16, 2024 | finance.yahoo.com
CRVS Apr 2024 4.000 put
March 13, 2024 | globenewswire.com
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
March 9, 2024 | finance.yahoo.com
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
March 4, 2024 | marketbeat.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in February
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,270,000 shares, a decline of 8.0% from the January 31st total of 1,380,000 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 206,300 shares, the short-interest ratio is currently 6.2 days.
February 17, 2024 | finance.yahoo.com
CRVS Mar 2024 3.000 put
February 12, 2024 | msn.com
Corvus Edges up on Disclosing Data
February 12, 2024 | finance.yahoo.com
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
February 8, 2024 | marketwatch.com
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation
February 8, 2024 | msn.com
Corvus lymphoma drug gets FDA orphan drug status
February 8, 2024 | finance.yahoo.com
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
February 6, 2024 | finance.yahoo.com
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
January 23, 2024 | finance.yahoo.com
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
January 5, 2024 | finance.yahoo.com
Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week
December 13, 2023 | markets.businessinsider.com
Maintaining Hold Rating on Corvus Pharmaceuticals Amid Steady but Unspectacular Clinical Progress
December 7, 2023 | msn.com
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
November 21, 2023 | finance.yahoo.com
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
November 9, 2023 | morningstar.com
Corvus Pharmaceuticals Inc CRVS
November 8, 2023 | finance.yahoo.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript
November 8, 2023 | finance.yahoo.com
Q3 2023 Corvus Pharmaceuticals Inc Earnings Call
November 7, 2023 | finance.yahoo.com
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

This Apple-like Innovator is Revolutionizing Healthcare (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

CRVS Media Mentions By Week

CRVS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRVS
News Sentiment
▼
0.53

0.42
▲
Average
Medical
News Sentiment

CRVS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRVS Articles
This Week
▼
2

1
▲
CRVS Articles
Average Week

Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:CRVS) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Dems have chosen Biden replacement?
Paradigm Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
This Could be Your “Big Money” AI Moment
InvestorPlace
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest
This military-backed stock “owns” AI market
Porter & Company
New Options need New Trading Strategies
Netpicks